
Creation of Pharmaceutical technological park on the territory of the FEZ of the Republic of Tajikistan
Country
Industry
Planned year
Project Details
Risk Allocation
The main participants in the implementation of the project to create an industrial park - state, region (project initiator). - Management Company - residents. The state and the region should be considered as one of the key participants in the project, it would be involved as a regulator, coinvestor and beneficiary in connection with the increase in tax revenues from the residents of the industrial park. Potential residents of the project are its key participants and stakeholders. They form preliminary requests for the provision of space and the required infrastructure. The risks associated with the construction process are fully borne by the initiator. The only way to minimize this risk is to choose a reliable contractor with experience in the construction of such facilities. Risks in the stages of developing the concept of the project (as well as marketing risks) also fall on the project initiator. Minimization of these risks is possible by choosing experienced designers and advertising agencies with a portfolio of similar projects.
Project Overview
The creation of the pharmaceutical techno park pursues several key goals related to the priority areas of socio-economic development of the Republic of Tajikistan. The main goal of the project is to promote the creation of production of medicines and dietary supplements as a significant sector of the economy of the Republic of Tajikistan. The desired effect will be achieved through the creation of a unique industrial site for this region, equipped with equipment for an integrated waste-free processing of raw materials using advanced technology for producing components, laboratories that comply with GMP standards. The implementation of the tasks set will allow achieving the goals that were set in the national project “State Program for the Development of the Pharmaceutical Industry in the Republic of Tajikistan for 2021-2025” and can contribute to the growth of exports of pharmaceutical products.
Project Details
The main participants in the implementation of the project to create an industrial park - state, region (project initiator). - Management Company - residents. The state and the region should be considered as one of the key participants in the project, it would be involved as a regulator, coinvestor and beneficiary in connection with the increase in tax revenues from the residents of the industrial park. Potential residents of the project are its key participants and stakeholders. They form preliminary requests for the provision of space and the required infrastructure. The risks associated with the construction process are fully borne by the initiator. The only way to minimize this risk is to choose a reliable contractor with experience in the construction of such facilities. Risks in the stages of developing the concept of the project (as well as marketing risks) also fall on the project initiator. Minimization of these risks is possible by choosing experienced designers and advertising agencies with a portfolio of similar projects.
The creation of the pharmaceutical techno park pursues several key goals related to the priority areas of socio-economic development of the Republic of Tajikistan. The main goal of the project is to promote the creation of production of medicines and dietary supplements as a significant sector of the economy of the Republic of Tajikistan. The desired effect will be achieved through the creation of a unique industrial site for this region, equipped with equipment for an integrated waste-free processing of raw materials using advanced technology for producing components, laboratories that comply with GMP standards. The implementation of the tasks set will allow achieving the goals that were set in the national project “State Program for the Development of the Pharmaceutical Industry in the Republic of Tajikistan for 2021-2025” and can contribute to the growth of exports of pharmaceutical products.